Eli Lilly Reports Results of Taltz (ixekizumab) in Head-to-Head P-IV IXORA-R Study for Moderate to Severe Plaque Psoriasis

Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext to Develop Therapies for Autoimmune Disorders


  • The P-IV IXORA-R study involves assessing of Taltz vs Tremfya (guselkumab) in 1,027 patients with moderate to severe plaque psoriasis for a total of 24 wks., with the primary analysis conducted at 12 wks.
  • The P-IV IXORA-R study results: met its 1EPs & 2EPs i.e, complete skin clearance as measured by PASI 100 @12wks. (41.3% vs 24.9%) & superior to Tremfya in achieving PASI 75 @2wk., PASI 90 @4 & 8 wks., PASI 100 @4, 8 & 24wks., sPGA 0 @12wk. and PASI 50 @1wk. respectively
  • Taltz is mAb targeting IL-17A cytokine and inhibits its interaction with the IL-17 receptor, thus inhibiting pro-inflammatory cytokines and chemokines while Tremfya is a mAb targeting p19 subunit of IL-23 and has received the FDA’s approval for mod. to sev. plaque psoriasis in July’2017

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Behance